Novo Holdings Buying Biopharma Co. Catalent In $16.5B Deal
By Al Barbarino · February 5, 2024, 9:45 AM EST
Novo Holdings, the controlling shareholder in Novo Nordisk Foundation, said Monday it has agreed to acquire Catalent in an all-cash transaction that values the pharmaceutical company at $16.5 billion, including debt,...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login